Substance / Medication

Isosorbide dinitrate

Overview

Active Ingredient
isosorbide dinitrate
RxNorm CUI
6058

Indications

Isosorbide dinitrate tablets are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of immediate-release oral isosorbide dinitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode.

Labeler: AvPAKUpdated: 2026-02-10T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Isosorbide dinitrate is contraindicated in patients who are allergic to isosorbide dinitrate or any of its other ingredients. Do not use isosorbide dinitrate in patients who are taking certain drugs for erectile dysfunction (phosphodiesterase inhibitors), such as sildenafil, tadalafil, or vardenafil

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

2 trials linked to this intervention

2
Total Trials
1
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Prevention of Preterm Labor by Isosorbide Dinitrate and Nitroglycerin Patch.
Ghafarzadeh Masoumeh, Shakarami Amir, Yari Fatemeh · Cardiovasc Hematol Disord Drug Targets · 2023
PMID: 37594102RCT
Combination Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD (HIDE): A Randomized, Placebo-Controlled, Pilot Trial.
Charytan David M, Hsu Jesse Y, Mc Causland Finnian R et al. · Kidney360 · 2020
PMID: 35372900RCTFull text (PMC)
A randomized controlled trial comparing isosorbide dinitrate-oxytocin versus misoprostol-oxytocin at management of foetal intrauterine death.
Arteaga-Troncoso Gabriel, Chacon-Calderon Aide E, Martinez-Herrera Francisco J et al. · PLoS One · 2019
PMID: 31751343RCTFull text (PMC)
The effect of sublingual isosorbide dinitrate on acute urinary retention due to benign prostatic hyperplasia.
Tadayyon Farhad, Izadpanahi Mohammadhossein, Aali Saeed et al. · Saudi J Kidney Dis Transpl · 2012
PMID: 22805391RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Isosorbide dinitrate (substance)
SNOMED CT
387332007
UMLS CUI
C0022252
RxNorm CUI
6058
Labeler
AvPAK

Clinical Data

This intervention maps to 11 entities in the Healos knowledge graph.

4
Conditions
4
Biomarkers
2
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.